Legal & General Group
SPRO icon

Legal & General Group’s Spero Therapeutics SPRO Stock Holding History

Legal & General Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,934
Closed -$1K – 3484
2022
Q2 		$1K Sell
1,934
-647
-25% -$1.88K ﹤0.01% 3504
2022
Q1 		$22K Buy
2,581
+114
+5% +$1.17K ﹤0.01% 3220
2021
Q4 		$40K Hold
2,467
– – ﹤0.01% 3080
2021
Q3 		$45K Sell
2,467
-92
-4% -$1.48K ﹤0.01% 3007
2021
Q2 		$36K Buy
2,559
+390
+18% +$5.45K ﹤0.01% 3066
2021
Q1 		$32K Sell
2,169
-8,231
-79% -$145K ﹤0.01% 2970
2020
Q4 		$202K Buy
10,400
+575
+6% +$8.96K ﹤0.01% 2417
2020
Q3 		$110K Sell
9,825
-700
-7% -$8.28K ﹤0.01% 2461
2020
Q2 		$142K Buy
10,525
+8,856
+531% +$99.4K ﹤0.01% 2438
2020
Q1 		$13K Sell
1,669
-455
-21% -$4.01K ﹤0.01% 3095
2019
Q4 		$20K Hold
2,124
– – ﹤0.01% 3190
2019
Q3 		$23K Buy
2,124
+650
+44% +$6.85K ﹤0.01% 3092
2019
Q2 		$17K Hold
1,474
– – ﹤0.01% 3260
2019
Q1 		$19K Buy
1,474
+455
+45% +$4.83K ﹤0.01% 3112
2018
Q4 		$6K Hold
1,019
– – ﹤0.01% 3324
2018
Q3 		$11K Hold
1,019
– – ﹤0.01% 3313
2018
Q2 		$15K Hold
1,019
– – ﹤0.01% 3252
2018
Q1 		$14K Hold
1,019
– – ﹤0.01% 3176
2017
Q4 		$12K Buy
+1,019
New +$12.5K ﹤0.01% 3220

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Legal & General Group's SPRO Position: Q3 2022 in Review

Legal & General Group sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 1,934 shares — an estimated $1K sold.

Legal & General Group first reported a position in SPRO in Q4 2017 and held it in 19 quarters. The position peaked at $202K in Q4 2020. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • Legal & General Group reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 1,934 Spero Therapeutics shares in Q3 2022, an estimated $1K.
  • Legal & General Group first reported a position in Spero Therapeutics in Q4 2017 and held it in 19 quarters.
  • Legal & General Group's Spero Therapeutics position peaked at $202K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.